| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 73171 |
模拟肽4-[2-(3,4,5,6-四氢嘧啶-2-基氨基)乙氧基]苯甲酰基-2-[N-(3-氨基-新戊-1-氨基甲酰基)]-氨乙基磺酰基-氨基-β-丙氨酸(IAC)缀合DOTA |
80 |
h |
2024-12-19 |
| 73172 |
DOTA-chCE7 DOTA标记的糖基化单克隆抗L1-CAM抗体chCE7 |
96 |
h |
2024-12-19 |
| 73173 |
Vc-MMAE， cas:646502-53-6，ADC定制 |
126 |
wyh |
2024-12-19 |
| 73174 |
Azido-PEG4-MMAE |
111 |
zyl |
2024-12-19 |
| 73175 |
cas:2055024-59-2，Fmoc-PEG2-Val-Cit-PAB-OH |
112 |
zyl |
2024-12-19 |
| 73176 |
Azide-PEG6-Val-Cit-PAB-PEG6- Biotin，ADC定制 |
111 |
wyh |
2024-12-19 |
| 73177 |
Ga-DOTA-(Asp)n 大环DOTA共轭(Asp)n肽 |
69 |
h |
2024-12-19 |
| 73178 |
cas:1807530-16-0，2-hydroxyethyl disulfide mono-Tosylate- ADC linker |
84 |
zyl |
2024-12-19 |
| 73179 |
DOTA偶联受体特异性肽 |
114 |
h |
2024-12-19 |
| 73180 |
聚乙二醇化DOTA-AHA基GdIII螯合物 PEGylated DOTA-based gadolinium(III) |
92 |
h |
2024-12-19 |
| 73181 |
PAMAM树状大分子DOTA缀合物 PAMAM–DOTA |
96 |
h |
2024-12-19 |
| 73182 |
ALD-tetra-EG-Osu的介绍 |
116 |
zyl |
2024-12-19 |
| 73183 |
SSTR2靶向肽Tyr(3)-奥曲肽(tate) |
212 |
h |
2024-12-19 |
| 73184 |
DOTA-D-Phe(1)-Tyr(3)-Octreotide |
88 |
h |
2024-12-19 |
| 73185 |
cas:55750-63-5，Mal-heptanoic NHS ester |
107 |
zyl |
2024-12-19 |
| 73186 |
DOTA-Fab-PEG24-EGF DOTA-PEG修饰曲妥珠单抗Fab片段偶联表皮生长因子 |
94 |
h |
2024-12-19 |
| 73187 |
cas:663599-10-8，DMAC-SPP |
100 |
zyl |
2024-12-19 |
| 73188 |
多甲基化的1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)配体 |
140 |
h |
2024-12-19 |
| 73189 |
PEG-pGlu(DOTA)8-LA4 |
52 |
h |
2024-12-19 |
| 73190 |
cas:937025-17-7，2,5-Dioxopyrrolidin-1-yl 2-oxo-6,9,12,15-tetraoxa-3-thiaoctadecan-18-oate |
140 |
zyl |
2024-12-19 |
| 73191 |
DOTA-Hyd-TRP PET示踪剂 |
101 |
h |
2024-12-19 |
| 73192 |
Ga-DOTATOC Ga-DOTA-D-Phe-Tyr-奥曲肽 |
136 |
h |
2024-12-19 |
| 73193 |
cas:1226371-65-8，N-(2-(2,5-Dimethylphenoxy)ethyl)-4-formylbenzamide |
77 |
zyl |
2024-12-19 |
| 73194 |
DOTA-ALN DOTA-阿仑膦酸盐 |
82 |
h |
2024-12-19 |
| 73195 |
氨氯地平DOTA偶联物 DOTA-Amlodipine |
141 |
h |
2024-12-19 |
| 73196 |
cas:906564-59-8，Propargyl-C2-NHS ester |
96 |
zyl |
2024-12-19 |
| 73197 |
DOTA-Gp2-EGFR DOTA螯合剂标记结合表皮生长因子受体EGFR靶向Gp2 |
84 |
h |
2024-12-19 |
| 73198 |
cas:894095-98-8，β-D-glucuronide-pNP-carbonate |
75 |
zyl |
2024-12-19 |
| 73199 |
DOTA结合肽功能化金纳米粒子 |
90 |
h |
2024-12-19 |
| 73200 |
90Y-DOTA-Bn 钇-90-DOTA-铃蟾肽 |
110 |
h |
2024-12-19 |
| 73201 |
cas:85916-13-8，NH-bis(C1-Boc)，亚氨基二乙酸二异丁酯 |
112 |
zyl |
2024-12-19 |
| 73202 |
Anti-CD19 (clone huB4)-Mc-MMAF-ADC分子 |
66 |
zyl |
2024-12-19 |
| 73203 |
Boc-Val-Cit-PAB-PNP cas:870487-10-8 |
65 |
zyl |
2024-12-19 |
| 73204 |
cas:2353409-70-6 MMAF-methyl ester |
127 |
zyl |
2024-12-19 |
| 73205 |
DOTA-ipilimumab 螯合剂DOTA缀合单克隆抗体ipilimumab |
79 |
h |
2024-12-19 |
| 73206 |
双功能单膦酸Ln-DOTA衍生物 |
104 |
h |
2024-12-19 |
| 73207 |
Cu-DOTA-阿伦膦酸盐 Cu-DOTA-alendronate |
100 |
h |
2024-12-19 |
| 73208 |
Mc-3377的介绍 |
82 |
zyl |
2024-12-19 |
| 73209 |
Endo-BCN-PEG4-Val-Cit-PAB-MMAF的介绍 |
80 |
zyl |
2024-12-19 |
| 73210 |
(DOTA)n-PAMAM-[尼妥珠单抗-F(ab’)2]的缀合物 |
83 |
h |
2024-12-19 |
| 73211 |
cas:2055041-39-7 Mal-PEG4-Val-Cit-PAB-OH |
116 |
zyl |
2024-12-19 |
| 73212 |
DBCO-PEG3-Val-Cit-PAB-PNP的介绍 |
130 |
zyl |
2024-12-19 |
| 73213 |
(DOTA)5-十氢赖氨酸(DOTA)5-decalysine |
116 |
h |
2024-12-19 |
| 73214 |
DOTA-HPMA缀合物 DOTA共轭N-(2-羟丙基)甲基丙烯酰胺聚合物 |
92 |
h |
2024-12-19 |
| 73215 |
G3-cNGR肽缀合物 |
117 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询